Prab at 00:02, 17 March 2025

2025-03-17T00:02:35Z

← Older revision		Revision as of 00:02, 17 March 2025
Line 33:		Line 33:
	[[Category:Nucleotide analogues]]		[[Category:Nucleotide analogues]]
	{{medicine-stub}}		{{medicine-stub}}
	~~{{No image}}~~
	<gallery>		<gallery>
	File:IDX-184 structure.png\|IDX-184 Structure		File:IDX-184 structure.png\|IDX-184 Structure
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T01:14:41Z

CSV import

← Older revision		Revision as of 01:14, 20 February 2025
Line 34:		Line 34:
	{{medicine-stub}}		{{medicine-stub}}
	{{No image}}		{{No image}}
			<gallery>
			File:IDX-184 structure.png\|IDX-184 Structure
			</gallery>

Prab: CSV import

2025-02-10T21:32:45Z

CSV import

← Older revision		Revision as of 21:32, 10 February 2025
Line 33:		Line 33:
	[[Category:Nucleotide analogues]]		[[Category:Nucleotide analogues]]
	{{medicine-stub}}		{{medicine-stub}}
			{{No image}}

Prab: CSV import

2024-02-29T03:20:35Z

CSV import

New page

'''IDX-184''' is an experimental antiviral drug that was developed by [[Idenix Pharmaceuticals]] for the treatment of [[Hepatitis C]]. It is a nucleotide analogue, specifically a prodrug of 2'-methylguanosine monophosphate, which acts as an inhibitor of the [[Hepatitis C virus]] (HCV) NS5B RNA-dependent RNA polymerase, an essential enzyme for the replication of the virus.

== History ==

IDX-184 was first synthesized and studied by Idenix Pharmaceuticals, a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of human viral diseases. The drug entered Phase I clinical trials in 2007, and Phase II trials in 2010. However, in 2013, the [[U.S. Food and Drug Administration]] (FDA) placed IDX-184 on clinical hold due to safety concerns, effectively halting further development.

== Mechanism of Action ==

As a nucleotide analogue, IDX-184 is metabolized in the liver to its active form, 2'-methylguanosine triphosphate. This active form inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing the replication of the virus. This mechanism of action is similar to that of other nucleotide analogues used in the treatment of HCV, such as [[Sofosbuvir]].

== Clinical Trials ==

In Phase I clinical trials, IDX-184 was found to be generally well-tolerated, with the most common side effects being mild to moderate in severity. In Phase II trials, the drug demonstrated potent antiviral activity, with a significant reduction in HCV RNA levels observed in patients treated with IDX-184.

However, in 2013, the FDA placed IDX-184 on clinical hold due to safety concerns. This decision was based on reports of serious cardiac events in patients treated with another nucleotide analogue, [[BMS-986094]], which is structurally similar to IDX-184. Despite the clinical hold, no such events were reported in the clinical trials of IDX-184.

== Future Development ==

Following the FDA's decision, Idenix Pharmaceuticals halted further development of IDX-184. The future of the drug is currently uncertain, with no plans announced for its resumption.

== See Also ==

* [[Hepatitis C]]
* [[Antiviral drug]]
* [[Nucleotide analogue]]
* [[Idenix Pharmaceuticals]]
* [[Sofosbuvir]]
* [[BMS-986094]]

[[Category:Antiviral drugs]]
[[Category:Hepatitis C]]
[[Category:Experimental drugs]]
[[Category:Nucleotide analogues]]
{{medicine-stub}}

IDX-184 - Revision history

Prab at 00:02, 17 March 2025

Prab: CSV import

Prab: CSV import

Prab: CSV import